This Article  • References  • Full text PDF  • Correction  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

A Perspective From the National Cholesterol Education Program

Scott M. Grundy, MD, PhD; DeWitt S. Goodman, MD; Basil M. Rifkind, MD; James I. Cleeman, MD

Arch Intern Med. 1989;149(3):505-510.

Abstract
• The guidelines developed by the Adult Treatment Panel of the National Cholesterol Education Program identified low density lipoprotein (LDL) as the major atherogenic lipoprotein, and high levels of LDL-cholesterol as the primary target for cholesterol-lowering therapy. Low levels of high density lipoprotein (HDL)-cholesterol were recognized as a major risk factor for coronary heart disease. This report reexamines in depth the recommendations of the Adult Treatment Panel on HDL-cholesterol. Two major questions are discussed: (1) Should HDL-cholesterol levels be measured in all adults, as recommended for total cholesterol? (2) Should patients found to have a low serum LDL-cholesterol level (35 mg/dL [<0.91 mmol/L]) enter medical therapy to raise the level? The guidelines of the Adult Treatment Panel are reaffirmed as appropriate from the current perspective. These guidelines recommend that HDL-cholesterol levels be determined in patients deemed to be at high risk for coronary heart disease and suggest that HDL measurement is optional for individuals with borderline-high total levels. The guidelines of the Adult Treatment Panel recommend that low HDL-cholesterol levels be raised mainly by hygienic means (ie, smoking cessation, weight loss, aerobic exercise). When drug therapy is required for high LDL-cholesterol levels in the presence of low HDL levels, cholesterol-lowering drugs that concomitantly raise HDL should be given first priority.

(Arch Intern Med. 1989;149:505-510)

Author Affiliations
From the National Cholesterol Education Program, National Heart, Lung, and Blood Institute, Bethesda, Md. The authors constitute the National Cholesterol Education Program Working Group on HDL.

Footnotes
Accepted for publication January 6,1989.

This article has been reviewed and approved by the National Cholesterol Education Program Coordinating Committee.

Reprint requests to Coordinator, National Cholesterol Education Program, Office of Prevention, Education, and Control, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892 (Dr Cleeman).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Phosphatidylinositol increases HDL-C levels in humans
Burgess et al.
J. Lipid Res. 2005;46:350-355.
ABSTRACT | FULL TEXT  

Differential response to low-fat diet between low and normal HDL-cholesterol subjects
Asztalos et al.
J. Lipid Res. 2000;41:321-328.
ABSTRACT | FULL TEXT  

Cholesterol-Reduction Intervention Study (CRIS) A Randomized Trial to Assess Effectiveness and Costs in Clinical Practice
Oster et al.
Arch Intern Med 1996;156:731-739.
ABSTRACT  

A Prospective, Randomized Trial of Phenytoin in Nonepileptic Subjects With Reduced HDL Cholesterol
Miller et al.
Arterioscler. Thromb. Vasc. Bio. 1995;15:2151-2156.
ABSTRACT | FULL TEXT  

Enthusiasm Misplaced?: Revisiting Cholesterol Screening
Oderkirk
J Holist Nurs 1994;12:414-424.
ABSTRACT  

Low Levels of High-Density Lipoprotein Cholesterol (Hypoalphalipoproteinemia) An Approach to Management
Rosenson
Arch Intern Med 1993;153:1528-1538.
ABSTRACT  

The Rationale for Lowering Serum Cholesterol Levels in American Children
Gidding
Arch Pediatr Adolesc Med 1993;147:386-392.
ABSTRACT  

Distribution of Lipid Phenotypes in Community-Living Men With Coronary Heart Disease: High Prevalence of Isolated Low Levels of High-Density Lipoprotein Cholesterol
Rubins et al.
Arch Intern Med 1992;152:2412-2416.
ABSTRACT  

Comparison of Gemfibrozil and Lovastatin in Patients With High Low-Density Lipoprotein and Low High-Density Lipoprotein Cholesterol Levels
McKenney et al.
Arch Intern Med 1992;152:1781-1787.
ABSTRACT  

Two Different Views of the Relationship of Hypertriglyceridemia to Coronary Heart Disease: Implications for Treatment
Grundy and Vega
Arch Intern Med 1992;152:28-34.
ABSTRACT  

Change in Cholesterol Awareness and Action: Results From National Physician and Public Surveys
Schucker et al.
Arch Intern Med 1991;151:666-673.
ABSTRACT  

National Education Programs Working Group Report on the Management of Patients with Hypertension and High Blood Cholesterol
Working Group on Management of Patients with Hyper
ANN INTERN MED 1991;114:224-237.
ABSTRACT  

Cholesterol and Coronary Heart Disease: Future Directions
Grundy
JAMA 1990;264:3053-3059.
ABSTRACT  

Within-Person Fluctuations of Serum Cholesterol and Lipoproteins
Mogadam et al.
Arch Intern Med 1990;150:1645-1648.
ABSTRACT  

Day-to-Day Variability of Serum Cholesterol, Triglyceride, and High-Density Lipoprotein Cholesterol Levels
Bookstein et al.
Arch Intern Med 1990;150:1653-1657.
ABSTRACT  

Nicotinic Acid and Hypercholesterolemia
HUTCHINSON
Arch Intern Med 1990;150:1548-1548.
ABSTRACT  

Management of Primary Mixed Hyperlipidemia With Lovastatin
Vega and Grundy
Arch Intern Med 1990;150:1313-1319.
ABSTRACT  

Population-Based Frequency of Dyslipidemia Syndromes in Coronary-Prone Families in Utah
Williams et al.
Arch Intern Med 1990;150:582-588.
ABSTRACT  

Comparison of Lovastatin and Gemfibrozil in Normolipidemic Patients With Hypoalphalipoproteinemia
Vega and Grundy
JAMA 1989;262:3148-3153.
ABSTRACT